Network pharmacology and molecular docking reveal mechanisms of amiodarone-induced pulmonary fibrosis

Huye Li1, Rubing Di1, Deyuan Kong2

  • 1The 4th People's Hospital of Qinghai Province, Xining, 810007, China.

Scientific Reports
|January 6, 2026
PubMed

Insights

This study used network pharmacology and molecular docking to uncover how amiodarone causes pulmonary fibrosis. It identified key targets and signaling pathways, offering insights into amiodarone

Area of Science:

  • Pharmacology and Toxicology
  • Computational Biology
  • Pulmonary Medicine

Background:

  • Pulmonary fibrosis is a severe outcome of chronic lung diseases with limited treatments.
  • Amiodarone, an antiarrhythmic drug, can cause pulmonary fibrosis, but its mechanisms are unclear.
  • Network pharmacology and molecular docking are emerging tools for understanding drug-induced toxicity.

Purpose of the Study:

  • To elucidate the molecular mechanisms of amiodarone-induced pulmonary fibrosis.
  • To identify key molecular targets and pathways involved in amiodarone's toxicity.
  • To provide a theoretical basis for future research and potential therapeutic strategies.

Main Methods:

  • Network pharmacology was used to predict amiodarone targets and identify pulmonary fibrosis-related genes.
  • Protein-protein interaction (PPI) networks and topological analysis identified hub genes.
  • Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed.
  • Molecular docking assessed amiodarone's binding affinity to key predicted targets.

Main Results:

  • Eight hub genes (ABCB1, ERBB2, XIAP, ABL1, SRC, HIF1A, AKT1, ADRB2) were identified.
  • Significant enrichment was found in EGFR/ErbB, VEGF, and renin secretion signaling pathways.
  • Molecular docking indicated favorable binding of amiodarone to hub proteins, particularly ABCB1 and AKT1.
  • A membrane-to-nucleus signaling framework was proposed, linking receptor activation to gene expression.

Conclusions:

  • This study systematically explored amiodarone-induced pulmonary fibrosis mechanisms using integrated computational approaches.
  • Key targets and signaling pathways provide new insights into amiodarone's pulmonary toxicity.
  • The proposed signaling framework offers a basis for future experimental validation and therapeutic development for amiodarone-related pulmonary complications.

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.9K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915
Drug Distribution: Tissue Binding01:21

Drug Distribution: Tissue Binding

Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
3.8K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.8K
Protein-Drug Binding: Mechanism and Kinetics01:16

Protein-Drug Binding: Mechanism and Kinetics

Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
1.6K